Manufacturing & Supply Partnering Terms & Agreements in Global Pharma, Biotech and Diagnostics (2014-2019) - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--May 17, 2019--
The “Global Manufacturing and Supply Partnering Terms and Agreements in Pharma, Biotech and Diagnostics 2014-2019” report has been added to ResearchAndMarkets.com’s offering.
This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology, device and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2014 to 2019.
The report provides a detailed understanding and analysis of how and why companies enter manufacturing and supply deals.
A supply or manufacturing agreement is normally between a product manufacturer and product owner in which an owner outsources the manufacture and supply of its product(s) to the service company in a defined territory.
Manufacturing and supply agreements provide a popular method of maximizing the value of a product launched into a market. The deals allow the product marketer to focus on its sales and marketing efforts whilst relying on a third party to manufacture and supply product on demand, enabling rapid response to market demands. It also ensures that the marketer does not need to invest in costly infrastructure and expertise ahead of knowing whether the product will be successful or sustainable.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,500 manufacturing and supply deals announced since 2014 as recorded in the deals and alliances database, including financial terms where available, plus links to online copies of actual manufacturing and supply contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of manufacturing and supply deal making and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in manufacturing and supply deal making as well as a discussion on the merits of the type of deal.
Chapters 3 and 4 provide an overview of the structure of manufacturing and supply deals. The chapter includes numerous case studies to enable understanding of both pure manufacturing and supply deals and multicomponent deals where manufacturing and supply forms a part.
Chapter 5 provides a review of the leading manufacturing and supply deals since 2014. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the deals and alliances database.
Chapter 6 provides a review of the top 50 most active biopharma companies in manufacturing and supply. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the deals and alliances database.
Chapter 7 provides a comprehensive and detailed review of manufacturing and supply deals signed and announced since 2014 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous table and figures that illustrate the trends and activities in manufacturing and supply deal making since 2014.
In addition, a comprehensive appendix is provided organized by manufacturing and supply company A-Z, stage of development, therapeutic target, technology type and deal type definitions. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about manufacturing and supply partnering in the research, development and commercialization of technologies and products.
The report is intended to provide the reader with an in-depth understanding of the manufacturing and supply trends and structure of deals entered into by pharma, biotech, device and diagnostics companies worldwide.
The report includes:
In the report, the available deals are listed by:
Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
The report provides comprehensive access to available records for over 2,500 manufacturing and supply deals, including contract documents where available.
Analyzing actual contract agreements allows assessment of the following:
Key Topics Covered
Chapter 1 - Introduction
Chapter 2 - Trends in Manufacturing and Supply Deal Making
Chapter 3 - Overview of Manufacturing and Supply Deal Structure
Chapter 4 - Overview of Supply Deal Structure
Chapter 5 - Leading Manufacturing and Supply Deals
Chapter 6 - Top 25 Most Active Manufacturing and Supply Dealmakers
Chapter 7 - Manufacturing and Supply Deals Contract Directory Since 2014
For more information about this report visit https://www.researchandmarkets.com/r/y991ks
View source version on businesswire.com:https://www.businesswire.com/news/home/20190517005375/en/
Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2019.
PUB: 05/17/2019 11:12 AM/DISC: 05/17/2019 11:12 AM